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Summary. Background: Two key limitations hamper intervention research in bronchiolitis: the
absence of a clear definition of disease, and the heterogeneous choice of outcome measures
in current clinical trials. We assessed how paediatricians and general practitioners (GPs)
perceived definition and clinically important outcomes in bronchiolitis. Methods: A nationwide
online survey (ABBA study) was conducted through the Portuguese Society of Paediatrics and
GPs’ mailing lists. We assessed agreement with statements on bronchiolitis definition, and
participants were asked to score the relative importance of several outcomes. Principal
component analysis (PCA) explored dimensions underlying disease definition. Outcomes
were ranked by mean score and proportion given highest score. Results: We included 514
paediatricians and 165 GPs (overall 59% were board-certified). Most paediatricians (76.5%)
agreed with a definition based on coryza, wheezing and/or crackles/rales, compared to 38.1%
GPs (P<0.001). Less than 5% physicians agreed with a definition commonly used in clinical
trials (<12months, first episode of wheeze). We retained three dimensions on PCA: one based
on coryza, rales/crepitations and no sudden onset; another on number of episodes and age;
and a third on wheeze. Dimensions varied by physician specialization and training (P<0.01).
Hospital admission and respiratory distress were top rated outcomes by both groups of
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physicians. Conclusions: Physician definitions of bronchiolitis have considerable variability
and often mismatch those of clinical trials. Rating of important outcomes was consistent. Our
results highlight the need for a robust standardized definition of acute bronchiolitis in infants
and support the development of a core outcome set for future clinical trials.Pediatr Pulmonol.
2016;51:724–732.  2015 Wiley Periodicals, Inc.
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INTRODUCTION
Acute viral bronchiolitis is the most common lower
respiratory tract infection in infants.1 It entails substantial
clinical and financial burden across different levels of
care. Treatment is controversial, and there is wide practice
variation and inconclusive evidence for many therapeutic
approaches.2,3 Systematic reviews in this field have
highlighted two shortcomings in clinical trial design: the
absence of a clear definition of disease, and the
heterogeneous choice of outcome measures.4,5
While bronchiolitis is a relatively straightforward
clinical diagnosis for most child health practitioners, no
standardized set of diagnostic criteria exists.1,6–10 A
Delphi panel from a local guideline in the United
Kingdom reported consensus on bronchiolitis as ‘a
seasonal viral illness characterised by fever, nasal
discharge and dry, wheezy cough’, with “fine inspiratory
crackles and/or high pitched expiratory wheeze”.11
However, definitions may vary by auscultatory findings,
age, number of episodes or other parameters.9,12,13
Furthermore, the label “bronchiolitis” may overlap with
acute wheezing and asthma, which hampers the interpre-
tation of current evidence.14,15 Empirical data is lacking
on physician’s perspectives of definitions and their
determinants.
The second issue relates to the inconsistency in
reported outcome domains measured in bronchiolitis
trials.4,16 This limits the interpretability of trial findings
and the opportunity for pooling results in meta-analysis.
Initiatives such as OMERACT and COMET have
supported the development and use of agreed standard-
ized collection of outcomes, that is, core outcome sets, to
be used, as a minimum, in all trials for a specific clinical
area.17,18 Core outcome sets should be meaningful for key
stakeholders. However, there is scarce evidence on which
outcomes in bronchiolitis are clinically relevant.
The ABBA survey aimed to assess the perspectives of
physicians, across the nation, on definition of bronchioli-
tis, and on clinical importance of different outcomes in
this field. We engaged and compared perspectives from
paediatricians and general practitioners (GPs), as both
groups are key stakeholders involved in the management
of bronchiolitis of varied severity at different levels of
care, and have distinct background and training that may
influence these perspectives.
MATERIALS AND METHODS
Study Design and Subjects
The ABBA study was a cross-sectional electronic
survey targeting paediatricians and GPs working in
Portugal, both board-certified physician specialists and
postgraduate physicians in a residency training program.
Paediatricians were current members of the Portuguese
Society of Paediatrics (SPP), which has an open
membership across levels of care. Electronic contact
information was provided by the organization, after
review and approval of the research protocol. Subjects
with invalid e-mail addresses were excluded. We reached
GPs who were registered in any of three national GP
mailing lists with the support of the Portuguese
Association of General Practitioners (APMGF).
Questionnaire
A multidisciplinary panel from the Pulmonology
section of the SPP and the APMGF designed a
questionnaire in Portuguese on various topics of
bronchiolitis; definition and outcomes are the focus of
this paper. The instrument was developed using a
structured approach. Based on a literature review and
the panel’s expertise, items were formulated for each
construct and examined for face validity. Item selection
and reduction was achieved through consensus. We
obtained 18 items on definitions and outcomes, and we
collected data on physicians’ training and workplace
(Appendix). Response formats included multiple choice
items, ordinal ratings (1–5) and 5-point Likert items
(ranging from disagree completely to agree completely).
First, we asked practitioners to express their level of
agreement with six statements on key history and clinical
findings in defining bronchiolitis. These included onset of
symptoms, preceding coryza, auscultatory findings
(crackles/rales and wheezing), upper age limit and
maximum number of episodes. Regarding outcomes,
participants were asked to score the importance given to
a predefined list of 12 outcomes in the interpretation and
applicability of clinical trial results.We included outcomes
that have been previously reported in bronchiolitis trials
(e.g., hospital admission, clinical severity), and added
outcomes recognised as relevant but often missing in this
field (e.g., quality of life, parent-reported symptoms). The
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survey was developed using the SurveyMonkey platform
(www.surveymonkey.com), and the instrument was pilot
tested for acceptability and feasibility.
Implementation
The survey ran from 5th April to 22nd May, 2013. A
modified Dillman technique was employed to optimize
the response rate, including up to four reminder e-mails
and a small incentive. Paediatricians were contacted
through personalized e-mail invitations, with a unique
link that prevented multiple entries. An e-mail invitation
with an open link was sent to each GP mailing list.
Consent was implied by survey completion, and data was
anonymized for analysis. The Ethics Committee of
Centro Hospitalar Lisboa Norte/Faculdade de Medicina
de Lisboa approved this study.
Preliminary data indicated approximately 1,300 mem-
bers of SPP from a universe of around 1,750 paedia-
tricians and 400 residents registered nationwide in 2011.
About 1,400 GPs were registered in all three mailing lists.
Previous electronic surveys performed within smaller
paediatric organizations reached response rates up to
60–75%. We anticipated 40–50% responses from paedia-
tricians, but a lower rate from GPs due to the method of
recruitment.
Statistical Analysis
Definitions of Bronchiolitis
We stratified results by paediatricians and GPs, and
compared responses to Likert items using the Mann-
Whitney test. We evaluated whether physician perspec-
tives were in agreement with two existing definitions, one
based on a consensus approach for a local guideline,11 the
other based on inclusion criteria used in recent random-
ized trials (operational criteria shown in Table S1), using
the x2 test.19,20
We used exploratory factor analysis to examine
whether any meaningful dimensions could be distin-
guished underlying the perspectives on definitions of
bronchiolitis.21 Principal component analysis (PCA) is
based on item correlations; items that correlate highly
with each other are clustered in one factor/component,
and share variance explained by the underlying dimen-
sion. PCA aims to explain as much total variance with a
minimal number of components. We performed PCA
including data from all participants on the six items on
definition of bronchiolitis. We determined the number of
components to retain based on two criteria: magnitude
of the eigenvalue >1 (main criteria) and examination of
scree plot. Selected components were rotated to facilitate
interpretation and to generate component loading scores,
which measure the association between items and the
underlying component. We used the varimax orthogonal
rotation, since components did not show considerable
correlation between each other (<0.2). Sampling
adequacy was assessed through the Kaiser–Meyer–Olkin
measure, and we used the Bartlett’s test of sphericity to
test for homogeneity. Items with conventional loading
>0.4 (absolute value) were interpreted for each compo-
nent. Using the resulting components as dependent
variables, we used multivariate analysis of variance
(MANOVA) to examine associations with group of
physician (paediatricians vs. GPs), training (resident vs.
specialist) and location (Lisbon and south vs. other
regions).
Outcomes in Bronchiolitis
We analyzed the distribution of scores given to each
outcomebypaediatricians andGPs, and identifiedoutcomes
that were rated 4 or 5 by over 80% of participants. Further,
we ranked outcomes within each subject (for equal scores,
standard competition ranking, that is, “1224” was used).
We then calculated for each outcome the proportion of
participants giving it the highest score/ranking. Overall
ranking of outcomeswas based on this proportion, aswell as
on the highest mean scores.
For all analyses, participants with incomplete responses
were excluded for the corresponding parameter, with
no imputation of missing data. P values <0.05 were
considered statistically significant. All analyses were
performed using SPSS for Mac and Windows (SPSS Inc,
version 21.0).
RESULTS
A flow diagram of participant recruitment is shown in
Figure 1. We sent 1,218 invitations to potentially
eligible SPP members, and included 514 (response rate
44%). Of approximately 1,400 GPs registered in mailing
lists, 165 subjects participated (estimated 12% response
rate). Complete responses were available from more
than 90% paediatricians and more than 70% GPs.
Table 1 summarizes the demographic characteristics of
included participants. For both paediatricians and GPs
the majority of responders were specialists (59.2%) and
worked in Lisbon or north of Portugal (74.9%). Of
paediatricians, 42.3% worked in all practice settings
(ambulatory, that is, outpatient, emergency department
and hospital), while most GPs provided paediatric
ambulatory care (94.5%), and 29.7% also worked in
paediatric emergency settings.
Definitions of Bronchiolitis: Descriptive Statistics
The perspectives of paediatricians (n¼ 494) and GPs
(n¼ 147) on key history and clinical findings are shown in
Figure 2 (number of episodes and age), and Figure 3 and
Table S2 (symptoms and signs). Most physicians on both
groups agreed or agreed completely with presence of
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wheezing on auscultation (92.9% paediatricians and
95.2% GPs) (P¼ 0.06). However, we found significant
differences between groups on all other parameters
(P< 0.001 for all comparisons). Most paediatricians
agreed or agreed completely with preceding coryza and
presence of crackles/rales (92.5% and 89.5%, respec-
tively), and disagreed or disagreed completely with
sudden onset of symptoms (68%). Further, they most
often restricted the diagnosis of bronchiolitis based on
number of episodes (up to three episodes 47.3%, only first
episode 32.4%), and upper age limit (up to 24 months
76.2%, up to 12 months 13.8%). On the contrary, 52.4%
GPs agreed or agreed completely with sudden onset of
symptoms, with a lower proportion than paediatricians
agreeing or agreeing completely with preceding coryza
and presence of crackles/rales (70.1% and 42.9%,
respectively). Also, many GPs did not restrict bronchioli-
tis by number of episodes (56.3%) or age (16.7%).
A definition of bronchiolitis close to the Nottingham
guideline had the agreement of 76.5% paediatricians and
38.1% GPs (P< 0.001). A commonly used clinical trial
definition of bronchiolitis (limited to a first episode of
wheezing below 12 months) had the agreement of only
4.1% paediatricians and 2.8% GPs (P< 0.001).
Fig. 1. Study flowchart of paediatricians and general practitioners.
TABLE 1—Demographic Characteristics of Paediatricians and General Practitioners
Demographic characteristics Paediatricians (n¼ 514)1 General practitioners (n¼ 165)1
Level of training—n (%)
Resident 215 (42) 62 (38)
Specialist 299 (58) 103 (62)
Time since graduation—median [P25-75] years
Resident 5 (4–6) 4 (3–5)
Specialist 14 (10–25) 9.5 (7–24.5)
Practice setting—n (%)2
Ambulatory care 319 (63) 156 (95)
Emergency department 432 (86) 49 (30)
Hospital care 362 (72) 1 (1)
Workplace—n (%)3
Lisbon region 206 (41) 65 (41)
North 175 (35) 50 (32)
Center 80 (16) 34 (21)
Other 42 (8) 10 (6)
1Results were calculated based on the number of respondents to a particular question; data available from n¼ 514 paediatricians and n¼ 165
general practitioners unless specified.
2Data available from n¼ 503 paediatricians; practice settings were not mutually exclusive.
3Data available from n¼ 503 paediatricians and n¼ 159 general practitioners.
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Definitions of Bronchiolitis: Factor Analysis
Principal component analysis was conducted with data
from644participants: the correlationmatrix between the six
items is shown on Table S3, each component’s eigenvalues
and percentages of variance explained are shown on
Table S4, and a scree plot on Figure S1. Three components
that explained 63.9% of the variability were retained. The
rotated component matrix is shown in Table 2. The first
component correlated with “coryza preceding symptoms”
and “crackles/rales on auscultation,” but was inversely
correlated with “sudden onset of symptoms” (Principal
Component 1-PC1, defined as “coryza and crackles/rales,
no sudden onset”). The second component was determined
by “number of episodes” and “age of the child” (PC2, “age
and episodes”), which varied together, with a stronger
correlation with the latter. The third component was mostly
correlated with “wheeze on auscultation” (PC3, “wheeze”).
Using MANOVA, we found significant associations of
underlying components with physician group (P< 0.001)
and level of training (P¼ 0.003), but not geographical
workplace (P¼ 0.811). In particular, paediatricians and
residents assigned higher scores on PC1 (i.e., they placed
more emphasis on this component), as compared to GPs
and specialists, respectively (P< 0.001). Compared to
GPs, paediatricians scored lower on PC2 (P¼ 0.011) and
PC3 (P¼ 0.002) (i.e., they placed less emphasis on these
components).
Outcomes in Bronchiolitis
Table 3 presents results on the relevance given by
physicians to different outcomes. Mean scores for all
outcomes were close to or above four in both groups, and
all medians were 4 (interquartile range 3–5). Most
outcomes were rated 4 or 5 by over 80% of participants in
both groups. Ranking outcomes by highest overall mean
score and by more frequent highest score led to
comparable results on the top outcomes, which were
hospital admission and respiratory distress for both
paediatricians and GPs. Outcomes which less than 80%
paediatricians scored 4 or 5 included feeding tolerance,
treatment harms, return visits, quality of life and sleep; the
latter three had the lowest mean scores of all outcomes.
Scores for need for oxygen therapy, recurrent wheezing
and asthma were more frequently less than 4 or 5 by GPs
when compared to paediatricians, both being among the
lowest mean scores in the GP group.
DISCUSSION
To our knowledge, this study provides the first
comprehensive assessment of bronchiolitis definitions
from physicians. The debate over the definition of disease
has lasted for decades, as the same diagnostic label is
applied to children with important differences in their
demographic, history and physical examination
Fig. 2. Perspectives of paediatricians and general practitioners on number of episodes (panel A)
and age (panel B) limits for the definition of bronchiolitis.
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features.6–13 Distinct perspectives have often been
attributed to a geographical divide between the North
American definition favouring a first episode of wheeze in
up to 1- or 2-year olds, and the use of the term in the
UnitedKingdom andAustralia, with crackles/crepitations
in younger infants as hallmarks, with or without
wheeze.8,9 However, empirical evidence in this field is
scarce. Our results suggest paediatricians have a broader
Fig. 3. Perspectives of paediatricians and general practitioners on key history and clinical
findings in bronchiolitis.
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view on auscultatory findings, including both wheezing
and crackles/rales. This is in line with the Nottingham
consensus, as well as with definitions mentioned in
current practice guidelines.22,23 We did find considerable
disagreement between paediatricians on age for acute
bronchiolitis and number of episodes, and none of the
guidance documents adheres to strict limits on these
parameters. Further, results from GPs clearly show a
different perspective for most items, with only wheezing
as a common feature. Thus we confirmed that physicians,
at both individual and specialty-level, define bronchiolitis
differently and we have identified heterogeneous clinical
items that must be addressed in any future standardized
definition of bronchiolitis.
The heterogeneity in disease definition has a consider-
able impact both for clinical practice and research in viral
acute bronchiolitis. Variability between centers in
diagnostic labelling of lower respiratory tract infections
in young children has been shown to influence treatment
practices, given the overlap with asthma and viral-
induced wheeze.24 We found a striking gap between
physicians’ perspectives and the definition used in recent
large clinical trials, mostly due to its 12-month limit and
restriction to a first episode. This has important
implications for the external validity and implementation
of trial findings. A majority of clinicians uses a broader
definition of bronchiolitis that includes older children
with recurrent episodes, and may find it hard to
extrapolate results from these trials. On the other hand,
they may not necessarily consider evidence from trials in
childrenwith recurrent pre-school wheezing as applicable
to bronchiolitis. Conversely, there are arguments in favour
TABLE 2—Perspectives on Definition of Bronchiolitis:
Principal Component Analysis With Factor Loadings,
Eigenvalues, and Explained Variances
1,2
Principal components
PC1 PC2 PC3
Item
Sudden onset of symptoms 0.643 0.125 0.327
Coryza preceding symptoms 0.743 0.112 0.298
Wheezing on auscultation 0.021 0.027 0.938
Crackles/rales on auscultation 0.685 0.099 0.010
Number of episodes 0.365 0.599 0.122
Age of the child 0.188 0.855 0.118
Eigenvalue before rotation 1,65 1,151 1,035
Explained variance (%) 26.723 18.798 18.408
Eigenvalue after rotation 1.603 1.128 1.104
1Factor loadings of absolute value 0.40 are shown in bold.
2Rotation method: varimax with kaiser normalization.
TABLE 3—Perspectives of Paediatricians and General Practitioners on Relevance of Outcomes in Bronchiolitis
Paediatricians (n¼ 466) General Practitioners (n¼ 119)
Outcome
Mean
score (SD)
Scored
4/5 by
>80%
% given
outcome as
highest score
Rank (by mean
score/by %
highest score)
Mean
score (SD)
Scored
4/5 by
>80%
% scoring
outcome as
highest score
Rank (by mean
score/by %
highest score)
Hospital
admission
4.38 (0.7) Yes 70 1/1 4.42 (0.8) Yes 74.8 2/2
Length of
hospital stay
4.29 (0.68) Yes 60.9 4/4 4.21 (0.85) Yes 59.7 5/5
Return visits 3.99 (0.82) No 44.2 10/9 4.11 (0.94) Yes 53.8 9/10
Respiratory
distress
4.37 (0.64) Yes 67.8 2/2 4.5 (0.77) Yes 81.5 1/1
Need for
oxygen
therapy
4.36 (0.62) Yes 66.3 3/3 3.99 (0.97) No 50.4 12/11
Feeding
tolerance
4 (0.7) No 40.8 9/11 4 (0.87) Yes 47.1 11/12
Duration of
illness
4.11 (0.74) Yes 50 6/8 4.2 (0.84) Yes 58.8 6/8
Sleep1 3.83 (0.83) No 35.6 12/12 4.18 (0.93) Yes 60.5 8/4
Treatment
harms
4.11 (0.79) No 51.5 7/7 4.19 (0.93) Yes 59.7 7/5
Quality of life1 3.96 (0.81) No 43.1 11/10 4.22 (0.89) Yes 59.7 4/5
Pulmonary
function2
4.2 (0.78) Yes 59.2 5/5 4.33 (0.94) Yes 73.1 3/3
Recurrent
wheezing
and asthma
4.1 (0.93) Yes 55.8 8/6 4.11 (0.97) No 58.8 10/8
1Parent-reported measures.
2Refers to long-term lung function prognosis.
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of a strict definition.25,26 Jartti et al. showed both age and
episodes are associated with factors such as viral
aetiology and atopic characteristics, which may influence
short- and long-term outcomes.13 In clinical trials,
randomisation can balance these or other confounders
that may affect treatment responses. However, both future
trials and epidemiological, prognostic and even transla-
tional research in this field would benefit from a more
robust case definition, with clear boundaries with other
wheezing disorders. Since a balance is needed between
study design and clinical practice, clarifying standardized
definitions in current practice guidelines would help.
Further, even if the clinical definition is kept broader,
researchers could agree on major subgroups for stratifi-
cation, based on current and upcoming markers for
domains such as host susceptibility, agent virulence,
immunopathogenesis, and environmental predictors.
Our exploratory factor analysis added to these findings
by identifying three key dimensions of correlated clinical
features that underlie individual perspectives, what we
may call “physician-based phenotypes” of bronchiolitis.
The weight given to each component varied by physician
specialty and training, but not by practice or geographical
location, hinting at differences due to clinical teaching
and experience, or severity of disease seen across settings.
These “physician-based phenotypes” should be put
against patient data to clarify whether valid clinical
phenotypes of bronchiolitis exist. Interestingly, two
dimensions match previously proposed clinical pheno-
types based on auscultatory findings: one characterised by
crackles (close to the “coryza and crackes/rales, no
sudden onset” component), the other by wheeze alone.9
The acoustic characteristics and pathological correlates of
adventitious sounds might be markers of distinct host
responses in bronchiolitis, and results from one small
study suggest they lead to different long-term respiratory
outcomes.27 Further, Sanchez et al found response to
bronchodilator in infants with bronchiolitis could be
predicted from wheeze characteristics.28 However, vali-
dating such phenotypes requires more evidence on their
association with disease severity, prognosis and possibly
treatment response. Furthermore, while a separate “age
and episodes” component signals that physicians perceive
these parameters independently, we’ve shown these and
other putative phenotype-defining traits interact and must
be approached coherently for an inclusive definition.29
Our study also addressed the critical issue of outcome
selection, which has been often overlooked in bronchioli-
tis intervention research. Previous systematic reviews of
trials have repeatedly found variability in measured
outcome domains and instruments used, noting the
absence of guidance on clinically important outcomes.4,5
Developing a core outcome set that is relevant to all
stakeholders would be a major step forward in acute viral
bronchiolitis research. We have made a first contribution
by evaluating the physician perspective, and found
hospital admission and respiratory distress as the highest
ranked and rated outcomes. Interestingly, there was
remarkable consistency between paediatricians and GPs
for these top outcomes, but some differences were found
in outcomes that scored below a commonly used
threshold for consensus (i.e., 80%). Outcomes such as
quality of life or sleep were more valued by GPs, which
highlights the need to incorporate stakeholder perspec-
tives across levels of care given the wide spectrum of
severity of bronchiolitis. Overall, all listed outcomeswere
highly rated by either clinician group, and should be
considered in a future core outcome set. Importantly, this
study is just a preliminary step in a structured core
outcome set development process.18,30 Our results may be
used to support a formal consensus approach involving
key stakeholders (other clinicians, researchers, parents,
regulators), across settings and internationally. Both
bronchiolitis definition and outcome selection could be
addressed in such an initiative.
Strengths and limitations of our study must be
considered. First, we focused on a limited predefined set
of clinical findings and outcomes, both of which may not
encompass all relevant items. Our purposewas to generate
representative data, and further in-depth analysis will
require qualitative research techniques. Second, the
demographics of participating paediatricians suggest
they are likely representative nationwide and across
settings, oversampled for residents. The sample of GPs
was smaller and many worked in paediatric emergency;
while primary care paediatrics is mainly provided by GPs,
there could be a possible bias of our sample towards views
closer to those of paediatricians. It should be noted that the
open link method of invitation for GPs carries a risk of
multiple responses by a same participant, although survey
settings were restricted to one response per computer.
Moreover, answers in this surveymaynot accurately reflect
individual practice when diagnosing bronchiolitis. Al-
thoughwe used standardized nomenclature of adventitious
sounds, terminology varies and reliability of stethoscope
examination is limited.31 Lastly, there may be limits to the
extrapolation of our nationwide results to other countries.
Stakeholder perspectives on relevance of outcomes are
likely to vary by factors such as organizational care and
societal values, and may not be generalizable worldwide.
On the other hand, Portugal has not been connoted to any of
the “geographical” bronchiolitis definitions, whichmay be
a strength of our study.
In summary, this survey showed paediatricians’ and
GPs’ definitions of bronchiolitis are heterogeneous and
often mismatch those of clinical trials. Exploratory
component analysis identified domains that underlie
different definitions. Our results highlight the need for a
robust standardized definition that accommodates rele-
vant subgroups and possibly phenotypes, suiting both
Perspectives on Definition and Outcomes in Bronchiolitis 731
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clinical practice, and research design. Further, we
identified outcomes of most relevance to physicians,
contributing to the development of a core outcome for
future clinical trials.
ACKNOWLEDGMENTS
We would like to acknowledge Pedro Mendes (Portu-
guese Society of Paediatrics) for the management of the
electronic contact database. We thank the Pulmonology
Society of the Portuguese Society of Paediatrics and the
Portuguese Association of General Practitioners for their
support. Maria Gabriela Andrade was integrated in a
research program for MD students (PIATI program) from
AssociaSc~ao de Estudantes da Faculdade de Cie^ncias
Medicas de Lisboa.
REFERENCES
1. SmythRL,OpenshawPJ.Bronchiolitis. Lancet 2006;368:312–322.
2. Bialy L, Foisy M, Smith M, Fernandes RM. The cochrane library
and the treatment of bronchiolitis in children: an overview of
reviews. Evid Based Child Health 2011;6:258–275.
3. Barben J, Kuehni CE, Trachsel D, Hammer J. Management of
acute bronchiolitis: can evidence based guidelines alter clinical
practice? Thorax 2008;63:1103–1109.
4. Fernandes RM, Bialy LM, Vandermeer B, Tjosvold L, Plint AC,
Patel H, Johnson DW, Klassen TP, Hartling L. Glucocorticoids for
acute viral bronchiolitis in infants and young children. Cochrane
Database Syst Rev 2013;6:Cd004878.
5. Hartling L, Fernandes RM, Bialy L, Milne A, Johnson D, Plint A,
Klassen TP, Vandermeer B. Steroids and bronchodilators for acute
bronchiolitis in the first 2 years of life: systematic review and
meta-analysis. BMJ 2011;342.
6. Winter ST. Bronchiolitis—What’s in a Name? Clin Pediatr (Phila)
1971;10:485–486.
7. McIntosh K. Bronchiolitis and asthma: possible common pathoge-
netic pathways. J Allergy Clin Immunol 1976;57:595–604.
8. McConnochie KM. Bronchiolitis. What’s in the name? Am J Dis
Child 1983;137:11–13.
9. Everard ML. Acute bronchiolitis and croup. Pediatr Clin North
Am 2009;56:119–133.
10. Court SDM. The definition of acute respiratory illnesses in
children. Postgrad Med J 49:771–776.
11. Lakhanpaul M, Armon K, Eccleston P, MacFaul R, Smith S, Vyas
H, Werneke U, Williams L, Stephenson T. An evidence based
guideline for the management of children presenting with acute
breathing difficulty. University of Nottingham. 2002. http://www.
nottingham.ac.uk/paediatric-guideline/breathingguideline.pdf
(accessed July 2014).
12. Mansbach JM, Camargo CA. Bronchiolitis: lingering questions
about its definition and the potential role of vitamin D. Pediatrics
2008;122:177–179.
13. Jartti T, Lehtinen P, Vuorinen T, Ruuskanen O. Bronchiolitis: age
and previous wheezing episodes are linked to viral etiology and
atopic characteristics. Pediatr Infect Dis J 2009;28:311–317.
14. Frey U, von Mutius E. The challenge of managing wheezing in
infants. N Engl J Med 2009;2130–2133.
15. Ducharme FM, Tse SM, Chauhan B. Diagnosis, management, and
prognosis of preschool wheeze. Lancet 2014;383:1593–1604.
16. Klassen TP. Determining the benefit of bronchodilators in bronchioli-
tis. When is there enough benefit to warrant adoption into clinical
practice? Arch Pediatr Adolesc Med 1996;150:1120–1121.
17. Tugwell P, Boers M, Brooks P, Simon L, Strand V, Idzerda L.
OMERACT: an international initiative to improve outcome
measurement in rheumatology. Trials 2007;8:38.
18. Williamson PR, Altman DG, Blazeby JM, Clarke M, Devane D,
Gargon E, Tugwell P. Developing core outcome sets for clinical
trials: issues to consider. Trials 2012;13:132.
19. Corneli HM, Zorc JJ, Mahajan P, Shaw KN, Holubkov R,
Reeves SD, Ruddy RM, Malik B, Nelson KA, Bregstein JS,
Brown KM, Denenberg MN, Lillis KA, Cimpello LB, Tsung
JW, Borgialli DA, Baskin MN, Teshome G, Goldstein MA,
Monroe D, Dean JM, Kuppermann N. Bronchiolitis study
group of the Pediatric Emergency Care Applied Research
Network (PECARN). A multicenter, randomized, controlled
trial of dexamethasone for bronchiolitis. N Engl J Med 2007;
357:331–339.
20. Plint AC, Johnson DW, Patel H, Wiebe N, Correll R, Brant R,
Mitton C, Gouin S, Bhatt M, Joubert G, Black KJ, Turner T,
Whitehouse S, Klassen TP. Pediatric Emergency Research Canada
(PERC). Epinephrine and dexamethasone in children with
bronchiolitis. N Engl J Med 2009;360:2079–2089.
21. Jolliffe IT. Principal components used with other multivariate
techniques. In: Jolliffe IT, editor. Principal component analysis.
New York: Springer New York; 2002. pp 199–231.
22. Subcommittee on Diagnosis and Management of Bronchiolitis.
Diagnosis and management of bronchiolitis. Pediatrics 2006;118:
1774–1793.
23. Scottish Intercollegiate Guidelines Network. Bronchiolitis in
children: a national clinical guideline. SIGN 2006. Available here:
http://www.sign.ac.uk/guidelines/fulltext/91/index.html
24. Mansbach JM, Espinola JA, Macias CG, RuhlenME, Sullivan AF,
Camargo CA Jr. Variability in the diagnostic labeling of
nonbacterial lower respiratory tract infections: a multicenter
study of children who presented to the emergency department.
Pediatrics 2009;123:e573–ee81.
25. KorppiM,KoponenP,NuolivirtaK.Upperagelimitforbronchiolitis:
12 months or 6 months? Eur Respir J 2012;39: 787–788.
26. Midulla F, Nenna R. Upper age limit for bronchiolitis: 12 months
or 6 months? Eur Respir J 2012;39:788–789.
27. Elphick HE, Ritson S, Rigby AS, Everard ML. Phenotype of acute
respiratory syncytial virus induced lower respiratory tract illness
in infancy and subsequent morbidity. Acta Paediatr 2007;96:
307–309.
28. Sanchez I, Vizcaya C, Garcı´a D, Campos E. Response to
bronchodilator in infants with bronchiolitis can be predicted
from wheeze characteristics. Respirology 2005;10:603–608.
29. Spycher BD, Silverman M, Kuehni CE. Phenotypes of
childhood asthma: are they real? Clin Exp Allergy 2010;40:
1130–1141.
30. Tugwell P, Boers M, D’Agostino M-A, Beaton D, Boonen A,
Bingham CO, 3rd, Choy E, Conaghan PG, Dougados M,
Duarte C, Furst DE, Guillemin F, Gossec L, Heiberg T, van der
Heijde DM, Hewlett S, Kirwan JR, Kvien TK, Landewe RB,
Mease PJ, Østergaard M, Simon L, Singh JA, Strand V, Wells
G. Updating the OMERACT Filter: implications of Filter
2. 0 to select outcome instruments through assessment of
“Truth”: content, face, and construct validity. J Rheumatol
2014;41:1000–1004.
31. Elphick HE, Lancaster GA, Solis A,Majumdar A, Gupta R, Smyth
RL. Validity and reliability of acoustic analysis of respiratory
sounds in infants. Arch Dis Child 2004;89:1059–1063.
SUPPORTING INFORMATION
Additional supporting information may be found in the
online version of this article at the publisher’s web-site.
732 Fernandes et al.
Pediatric Pulmonology
